# Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

> **NCT06815497** · PHASE2 · RECRUITING · sponsor: **Tyler J Curiel** · enrollment: 33 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Telmisartan

## Key facts

- **NCT ID:** NCT06815497
- **Lead sponsor:** Tyler J Curiel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-21
- **Primary completion:** 2027-04-14
- **Final completion:** 2029-05-14
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06815497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06815497, "Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06815497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*